Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01534208
Recruitment Status : Completed
First Posted : February 16, 2012
Results First Posted : July 24, 2014
Last Update Posted : July 24, 2014
Sponsor:
Information provided by (Responsible Party):
Repros Therapeutics Inc.

Brief Summary:
ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.

Condition or disease Intervention/treatment Phase
Secondary Hypogonadism Drug: Androxal Phase 3

Detailed Description:
This study is a phase III, open label safety study with a six month active dosing period. All subjects will be started at 12.5 mg Androxal and titrated to 25 mg if needed. Safety will be assessed by physical and visual acuity exams, slit lamp eye exams, clinical laboratory tests and adverse event reporting.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 499 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
Study Start Date : May 2012
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Androxal 12.5 mg
Androxal 12.5 mg daily
Drug: Androxal
Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
Other Name: Enclomiphene citrate

Experimental: Androxal 25 mg
Androxal 25 mg daily
Drug: Androxal
Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
Other Name: Enclomiphene citrate




Primary Outcome Measures :
  1. Change From Baseline in Total Morning Testosterone at 26 Weeks [ Time Frame: 6 months ]
    Changes in values from baseline of total morning testosterone levels at Week 26

  2. Change From Baseline in LH [ Time Frame: 6 months ]
    Mean change from baseline in LH at end of treatment (26 weeks)

  3. Absolute Values of Morning Testosterone [ Time Frame: 6 months ]
    Absolute values of morning testosterone at end of treatment (26 weeks)

  4. Mean Change From Baseline FPG [ Time Frame: 6 months ]
    Mean changes in Fasting Plasma Glucose from baseline to end of treatment (26 weeks)

  5. Change From Baseline in BMI [ Time Frame: 6 months ]
    Mean change from baseline in BMI at end of treatment (26 weeks)

  6. Change From Baseline in FSH [ Time Frame: 6 months ]
    Change from baseline in FSH at end of treatment (26 weeks)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Secondary hypogonadal males between the ages of 18 and 65
  2. Men currently using topical testosterone products should wash-out for at least 7 days before Visit 1.
  3. All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor)
  4. Previously or concurrently diagnosed as having secondary hypogonadism and confirmed with morning testosterone level < 350 ng/dL for men age < 55 and < 300ng/dl for men age 55-65
  5. LH < 15mIU/mL (at Visit 1 only)
  6. Ability to complete the study in compliance with the protocol
  7. Ability to understand and provide written informed consent.

Exclusion Criteria:

  1. Use of an injectable pelleted testosterone within 6 months prior to study (men currently on topical testosterone products may be enrolled in the study after a 7-day washout period).
  2. Use testosterone injection, spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
  3. Use of Clomid in the past year
  4. Uncontrolled hypertension based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study.
  5. A hematocrit ≥ 51% or a hemoglobin ≥ 17 g/dL
  6. Clinically significant abnormal findings on screening examination, based on the Investigator's assessment.
  7. Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
  8. Known hypersensitivity to Clomid
  9. Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any trace of posterior subcapsular cataract)
  10. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
  11. Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, or tumors of the pituitary)
  12. Current or history of breast cancer
  13. Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA > 3.6
  14. Presence or history of known hyperprolactinemia with or without a tumor
  15. Chronic use of medications use such as glucocorticoids
  16. Chronic use of narcotics
  17. Subjects know to be positive for HIV
  18. End stage renal disease
  19. Subjects with cystic fibrosis (mutation of the CFTR gene)
  20. Enrollment in a previous Androxal study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01534208


Locations
Show Show 31 study locations
Sponsors and Collaborators
Repros Therapeutics Inc.
Investigators
Layout table for investigator information
Study Chair: Joseph S Podolski Repros Therapeutics Inc.

Additional Information:
Layout table for additonal information
Responsible Party: Repros Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT01534208    
Other Study ID Numbers: ZA-300
First Posted: February 16, 2012    Key Record Dates
Results First Posted: July 24, 2014
Last Update Posted: July 24, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Hypogonadism
Neoplastic Processes
Neoplasms
Pathologic Processes
Gonadal Disorders
Endocrine System Diseases
Citric Acid
Sodium Citrate
Enclomiphene
Clomiphene
Zuclomiphene
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators